Functional BCL-2 rs2279115 Promoter Noncoding Variant Contributes to Glioma Predisposition,Especially in Males

Abstract

As a crucial oncogene, B cell lymphoma-2 (BCL-2) could promote cancer cell survival by inhibiting apoptosis via suppressing activation of proapoptotic proteins, such as BAX and BAK. There is a functional rs2279115 genetic polymorphism locating in BCL-2 promoter and deregulating BCL-2 expression. However, it is still largely undefined how BCL-2 rs2279115 promoter noncoding genetic variant is involved in glioma development. We examined the association between BCL-2 rs2279115 and glioma risk using a case–control approach. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by logistic regression adjusted by age and sex. Our results demonstrated that BCL-2 rs2279115 was significantly associated with glioma risk. The odd of individuals harboring A allele (CA + AA genotype) was 0.50 (95% CI = 0.39–0.64, p = 1.0 × 10⁻⁷) compared with CC genotype carriers. Stratification analyses by sex elucidated that BCL-2 rs2279115 was significantly associated with glioma risk in males (OR = 0.41, 95% CI = 0.30–0.58, p = 1.0 × 10⁻⁷), but not in females (p > 0.05). In summary, our results indicate that the functional BCL-2 rs2279115 genetic variant contributes to glioma predisposition and suggest prevalent involvement of regulatory genetic variations in glioma development.

Get full access to this article

View all access options for this article.

References

Adams

J.M.

, and Cory

(2007). The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 26, 1324–1337.

Ashkenazi

, and Dixit

V.M.

(1998). Death receptors: signaling and modulation. Science, 281, 1305–1308.

Ashkenazi

, Fairbrother

W.J.

, Leverson

J.D.

, and Souers

A.J.

(2017). From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov, 16, 273–284.

Chen

, Hu

, Wang

L.E.

, Sturgis

E.M.

, El-Naggar

A.K.

, Zhang

, et al. (2007). Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis, 28, 2008–2012.

Chen

Y.D.

, Lu

, Wei

, Han

, Wang

, Jiang

, et al. (2014). 1p34.2 rs621559 and 14q21 rs398652 leukocyte telomere length-related genetic variants contribute to glioma susceptibility. J Neurooncol, 119, 71–78.

Danial

N.N.

, and Korsmeyer

S.J.

(2004). Cell death: critical control points. Cell, 116, 205–219.

Elmore

(2007). Apoptosis: a review of programmed cell death. Toxicol Pathol, 35, 495–516.

Goodenberger

M.L.

, and Jenkins

R.B.

(2012). Genetics of adult glioma. Cancer Genet, 205, 613–621.

Hardwick

J.M.

, and Soane

(2013). Multiple functions of BCL-2 family proteins. Cold Spring Harb Perspect Biol, 5, 1–22.

10.

Hockenbery

D.M.

(1994). bcl-2 in cancer, development and apoptosis. J Cell Sci Suppl, 18, 51–55.

11.

Ichim

, and Tait

S.W.

(2016). A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer, 16, 539–548.

12.

Kelly

P.N.

, and Strasser

(2011). The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ, 18, 1414–1424.

13.

Kinnersley

, Labussiere

, Holroyd

, Di Stefano

A.L.

, Broderick

, Vijayakrishnan

, et al. (2015). Genome-wide association study identifies multiple susceptibility loci for glioma. Nat Commun 6, 8559.

14.

, Qian

, Wang

, Teng

, and Zhang

(2014) Association of BCL2–938C > A genetic polymorphism with glioma risk in Chinese Han population. Tumour Biol, 35, 2259–2264.

15.

Loriot

, Mordant

, Dugue

, Geneste

, Gombos

, Opolon

, et al. (2014). Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer. Cell Death Dis 5, e1423.

16.

, Chen

Y.D.

, Han

, Wei

, Ge

, Pan

, et al. (2014). A RAD52 genetic variant located in a miRNA binding site is associated with glioma risk in Han Chinese. J Neurooncol, 120, 11–17.

17.

Maher

E.A.

, Furnari

F.B.

, Bachoo

R.M.

, Rowitch

D.H.

, Louis

D.N.

, Cavenee

W.K.

, et al. (2001). Malignant glioma: genetics and biology of a grave matter. Genes Dev, 15, 1311–1333.

18.

Melin

B.S.

, Barnholtz-Sloan

J.S.

, Wrensch

M.R.

, Johansen

, Il'yasova

, Kinnersley

, et al. (2017). Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet, 49, 789–794.

19.

Mirkovic

, Voehringer

D.W.

, Story

M.D.

, McConkey

D.J.

, McDonnell

T.J.

, and Meyn

R.E.

(1997). Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene, 15, 1461–1470.

20.

Ohbu

, Saegusa

, Kobayashi

, Tsukamoto

, Mieno

, Kakita

, et al. (1997). Expression of bcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis. Cancer, 79, 1287–1293.

21.

Omuro

, and DeAngelis

L.M.

(2013). Glioblastoma and other malignant gliomas: a clinical review. JAMA, 310, 1842–1850.

22.

Ouyang

, Shi

, Zhao

, Wang

F.T.

, Zhou

T.T.

, Liu

, et al. (2012). Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif, 45, 487–498.

23.

Pan

, Yang

, Wei

, Chen

, Ge

, Zhang

, et al. (2015). Functional BCL-2 regulatory genetic variants contribute to susceptibility of esophageal squamous cell carcinoma. Sci Rep 5, 11833.

24.

Pardo

O.E.

, Arcaro

, Salerno

, Raguz

, Downward

, and Seckl

M.J.

(2002). Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem, 277, 12040–12046.

25.

Park

B.L.

, Kim

L.H.

, Cheong

H.S.

, Cho

H.Y.

, Kim

E.M.

, Shin

H.D.

, et al. (2004). Identification of variants in cyclin D1 (CCND1) and B-Cell CLL/lymphoma 2 (BCL2). J Hum Genet, 49, 449–454.

26.

Rajaraman

, Melin

B.S.

, Wang

, McKean-Cowdin

, Michaud

D.S.

, Wang

S.S.

, et al. (2012). Genome-wide association study of glioma and meta-analysis. Hum Genet, 131, 1877–1888.

27.

Seto

, Jaeger

, Hockett

R.D.

, Graninger

, Bennett

, Goldman

, et al. (1988). Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J, 7, 123–131.

28.

Shete

, Hosking

F.J.

, Robertson

L.B.

, Dobbins

S.E.

, Sanson

, Malmer

, et al. (2009) Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet, 41, 899–904.

29.

Strzyz

(2017). Cell death: pulling the apoptotic trigger for necrosis. Nat Rev Mol Cell Biol 18, 72.

30.

Taylor

R.C.

, Cullen

S.P.

, and Martin

S.J.

(2008). Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol, 9, 231–241.

31.

Yang

, Gao

, Ma

, Ren

, Chen

, Liang

, et al. (2016). Association of the functional BCL-2 rs2279115 genetic variant and small cell lung cancer. Tumour Biol, 37, 1693–1698.

32.

Yip

K.W.

, and Reed

J.C.

(2008). Bcl-2 family proteins and cancer. Oncogene, 27, 6398–6406.

33.

Young

R.L.

, and Korsmeyer

S.J.

(1993). A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol, 13, 3686–3697.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.09 MB

0.02 MB